1. Introduction {#sec1}
===============

Approximately 15 to 30% of thyroid nodules evaluated by fine-needle aspiration (FNA) are classified as indeterminate, including atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS, category III), follicular neoplasm or suspicious for follicular neoplasm (FN/SFN, category IV), and suspicious for malignancy (SM, category V) according to the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) \[[@B1]\]. The present guidelines recommend repeated FNA for category III lesions, lobectomy for category IV lesions, and repeated category III lesions \[[@B2]--[@B4]\]. However, the malignancy risk in TBSRTC categories III and IV ranges between 5% and 30% after surgery \[[@B5]\]. Patients with cytological ITNs are often referred for diagnostic surgery, though most of these nodules finally prove to be benign \[[@B6]\]. The Afirma gene expression classifier (GEC) measures the expression of 167 gene transcripts to determine whether the nodules are benign or malignant \[[@B7]\]. In 2012, a prospective, multicenter validation trial of the Afirma GEC involving 265 ITNs demonstrated a sensitivity of 92% and a specificity of 52% in TBSRTC III/IV nodules \[[@B7]\]. In the last decade, some studies \[[@B8]--[@B10]\] have evaluated its effects on ITNs but the results were inconsistent, probably due to the rates of indeterminate biopsy result varying among the hospitals and tertiary centers \[[@B11]\]. In 2016, a meta-analysis including seven studies of GEC revealed the pooled sensitivity of 95.7% and the specificity of 30.5% and concluded it as a rule-out malignancy test \[[@B9]\]. However, Sacks et al. demonstrated that there were no significant changes in surgery rates and malignant prevalence by comparing pre-Afirma and post-Afirma cases \[[@B12]\]. We checked the database and included 18 newly published studies to provide a more comprehensive analysis on the diagnostic performance of GEC and discuss its role in decision-making process of thyroid surgery.

2. Methods {#sec2}
==========

2.1. Data Sources and Search {#sec2.1}
----------------------------

We searched PubMed and Embase for studies published between January 2005 and December 2018. We also checked the Cochrane Library with the same keywords. A total of 126 studies were identified. After excluding duplicates, reviews, commentary, insufficient data, 18 studies \[[@B7], [@B12]--[@B29]\] examined the performance of GEC for ITNs. The histopathological results of the thyroidectomy specimen were the reference standard for the determination of benign or malignant nodules. We used a QUADAS-2 report \[[@B28]\] for the included studies to assess the bias and applicability of the test.

In PubMed database, the keywords were a combination of "Thyroid Nodule/diagnosis"\[Majr\] OR "Thyroid Nodule/pathology"\[Majr\] OR "Thyroid Nodule/surgery"\[Majr\] AND "gene expression classifier" OR "GEC". Embase search was done using the following keywords ("Thyroid Nodule/diagnosis"\[Mesh\] OR "Thyroid Nodule/surgery"\[Mesh\]) AND ("gene expression classifier" OR "GEC"). Meanwhile, we checked the references of included literatures to identify additional relevant publications.

2.2. Study Selection and Eligibility Criteria {#sec2.2}
---------------------------------------------

### 2.2.1. Inclusion Criteria for Studies {#sec2.2.1}

Indeterminate thyroid results via FNA that included categories III, IV, and V.Use of Afirma GEC test as an index test.Histopathologic results diagnosis from thyroidectomy surgical specimens as gold reference standard.Incidental microcarcinomas were not included in the analysis.

### 2.2.2. Exclusion Criteria for Studies {#sec2.2.2}

Opinions, reviews, commentary, case reports, and insufficient data.Lack of clinical characteristics of nodules, clear inclusion, and exclusion criteria.Absence of surgical histopathology results.

We screened the studies following the process that was illustrated in [Figure 1](#fig1){ref-type="fig"}. A total of 18 studies met the inclusion criteria via the evaluation of QUADAS-2 questionnaire \[[@B28]\].

2.3. Data Extraction {#sec2.3}
--------------------

Two authors were engaged in reviewing the literatures from PubMed database and Embase independently according to the inclusion criteria. All conflicts were resolved through consensus within the groups. A third reviewer assessed all the discrepant items and the major opinion was used to resolve the disagreement between the reviewers.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The present work followed the structure of the PRISMA statement. Analyses were conducted using MetaDisc 1.4. We calculated pooled sensitivity, specificity, DOR, SROC, and the prediction ellipses for the hierarchical ordinal regression for ROC curves (HROC) model. We also used Cochrane Review Manager Version 5.3 (RevMan; 2014) to perform risk of bias evaluations of studies included in this meta-analysis. Deek\'s funnel plot asymmetry test was adopted as the way of evaluating publication bias both in each section of the analysis.

3. Results {#sec3}
==========

3.1. Performance of Gene Expression Classifier in ITNs {#sec3.1}
------------------------------------------------------

A total of 18 studies \[[@B7], [@B12]--[@B29]\] meeting eligibility criteria were included in this meta-analysis, main characteristics of all selected reports were showed in [Table 1](#tab1){ref-type="table"}. We got 5290 patients assessed by FNA; 3390 nodules were categorized as ITNs, 2889 of which underwent gene expression classifier finally. Of the 2889 nodules with GEC results, 1187 (41.1%) were GEC-benign, 1599 (55.4%) were GEC-suspicious, and 101 (3.6%) were GEC-unsatisfactory. Of 1187 benign nodules, 228 (19.2%) benign nodules underwent surgery; 27 (11.8%) of them proved to be malignant while 201 (88.2%) were benign after thyroidectomy. Meanwhile, 1371 of 1599 nodules categorized as suspicious GEC results underwent surgery; 617 (45.0%) of them were malignant while 754 (55.0%) were benign. In 101 nodules with GEC-unsatisfactory results, 18 (3.6%) had surgery, 1 (5.6%) proved to be malignant while 17 (94.4%) were benign. Since not all studies included cytological subtypes performance of with GEC results, we calculated nodules with cytological subtypes (N=1628), which are given in [Table 2](#tab2){ref-type="table"}. After underwent surgery, all samples were proved to be either benign or malignant. [Table 3](#tab3){ref-type="table"} demonstrates the correlation between overall surgery follow-up and GEC results with available data. After surgical resection, the malignant call risk was 645/1617 (39.9%) while the benign call rate was 972/1617 (60.1%).

Several original articles missed part of the detailed pathological results of surgical samples, just described surgical results as benign or malignant. We collected the available pathological information. [Table 4](#tab4){ref-type="table"} shows the surgical pathological diagnoses at resection of Afirma results with cytological subtypes (with as much as available data) (N=225).

The most surgical benign nodules were follicular adenoma, adenomatoid nodule, thyroiditis, etc. The most surgical malignant lesions are classic variant of papillary thyroid carcinomas (cvPTC) and follicular variant of papillary thyroid carcinomas (fvPTC). The summary of final histopathologic subtypes of all samples are available in [Table 5](#tab5){ref-type="table"} (N=960). The benign thyroid nodules proved by surgical resection are follicular adenoma, benign follicular nodule and adenomatoid nodule, etc. The most surgical malignant lesions are cvPTCs and fvPTCs.

3.2. Summary Estimates of Sensitivity, Specificity, NPV, PPV, DOR, and Summary ROC Curves {#sec3.2}
-----------------------------------------------------------------------------------------

The analysis of diagnostic threshold revealed the spearman correlation coefficient was 0.414, p=0.111. We concluded that there was no threshold effect in this meta-analysis.

[Table 6](#tab6){ref-type="table"} shows the pooled sensitivity, specificity, confidence intervals and heterogeneity results of the test. The pooled sensitivity of GEC is 95.5% (95% CI 93.5%--97.0%, I^2^ value 65.0%, p \< 0.001), the pooled specificity is 22.1% (95% CI 19.4%-24.9%, I^2^ value 89.1%, p \< 0.001), the PLR is 1.167 (95% CI 1.088--1.252, I^2^ value 77.5%, p \< 0.001), the NLR is 0.285 (95% CI 0.199--0.410, I^2^ value 0.00%, p= 0.778), the NPV is 88.2% (95% CI 0.833--0.921, I^2^ value 41.1%, p \< 0.001), the PPV is 44.3% (95% CI 0.416--0.471, I^2^ value 65.0%, p \< 0.001), and the DOR is 5.25 (95% CI 3.42--8.04, I^2^ value 0.00%, Q 9.42, p=0.855). The forest plots exhibit the pooled sensitivity, specificity, PLR, NLR, diagnostic score, and DOR (Figures [2(a)](#fig2){ref-type="fig"}--[2(e)](#fig2){ref-type="fig"}). Since the false negative and true negative values of two included studies \[[@B17], [@B27]\] were 0, the original data of these two studies was dropped by the MetaDisc software.

Since the I^2^ values of the sensitivity, specificity, PLR, and NPV were more than 50%, we conducted the metaregression analysis (inverse variance weights) to investigate the sources of heterogeneity. The metaregression revealed whether the original GEC test studies were conducted in single or multiple centers was the main source of heterogeneity (p=0.032) ([Table 7](#tab7){ref-type="table"}).

The bivariate logistic regression is described in [Table 8](#tab8){ref-type="table"}. The ROC plane is in [Figure 3](#fig3){ref-type="fig"}. The SROC curve has been shown in [Figure 4](#fig4){ref-type="fig"} with prediction and confidence contours. The area under the curve (AUC) is 0.73. The evaluation of bias in this meta-analysis is in [Figure 5](#fig5){ref-type="fig"}.

3.3. Publication Bias {#sec3.3}
---------------------

We conducted Deek\'s funnel plot asymmetry test to evaluate publication bias in each section of the analysis ([Figure 6](#fig6){ref-type="fig"}). As the p-value is 0.34, we concluded that no obvious publication bias was found in every section of this meta-analysis.

4. Discussion {#sec4}
=============

Thyroid cytopathological ITNs are usually referred to thyroidectomy or lobectomy and up to 74% of patients with cytologically indeterminate nodules are operated \[[@B5]\]. To some extent, ultrasound-guided FNA with on-site cytopathology improves both adequacy and accuracy of preoperative diagnoses in ITNs.

The Afirma GEC developed by Veracyte (South San Francisco, CA) measures 167-gene mRNA expression panel of thyroid nodules to distinguish benign and malignant nodules. Since commercially available in 2011, the test has significantly prevented avoidable thyroid surgeries. Most studies regarded it as a tool to rule out malignant lesions and potential for risk assessment \[[@B7], [@B9]\].

A systematic review \[[@B30]\] which evaluated the methods of studies of GEC and concluded the most common methodologic drawback was lack of reference standard diagnosis analyses to unexcised ITNs with GEC-benign results, which resulted in overestimating the specificity. The performance of GEC could range widely between tertiary care facilities and comprehensive hospitals \[[@B9]\]. Patients\' selection for surgery may affect both accuracy and clinical applicability of the test. Noureldine et al. proposed a surgical management algorithm and found that GEC did not change the surgical decision-making process significantly \[[@B18]\]. After long follow-up period, there were no significant malignancy differences between the two groups \[[@B31]\].

One earlier meta-analysis \[[@B9]\] assessed the performance of GEC. By adding newly published studies of GEC in recent years and pathological results after surgery, our results revealed that the GEC\'s sensitivity was 95.4%, the specificity was 22.3%. The diagnostic profiling of GEC is mainly limited to papillary and follicular thyroid carcinoma partly due to the relatively low prevalence of medullary and anaplastic thyroid cancer. Our present data revealed that the pooled NPV of GEC was not as high as previous studies \[[@B7], [@B9], [@B32]\].

The present study summarized the final pathological outcomes of GEC nodules after surgery. The high sensitivity and NPV make GEC as an effective approach to rule out malignant lesions in thyroid nodules with an indeterminate cytology. Taking the pooled postoperative pathological data into consideration, most GEC-suspicious nodules with benign pathological results after surgery are follicular adenomas (31.2%), benign follicular nodules (15.6%) and adenomatoid nodules (13.0%). The adenomatoid nodule is featured as a densely cellular follicular proliferation lack of capsule in histology. In the TBSRTC, the adenomatoid nodule is divided into category III or category IV \[[@B1]\]. According to a study of 234 thyroid FNA, the adenomatoid nodules were easily incorrectly diagnosed as follicular neoplasms \[[@B33]\]. Chronic thyroid inflammation is commonly regarded as chronic lymphocytic thyroiditis (CLT), characterized with diffuse lymphocytic infiltration in the thyroid glands. The impact of CLT on clinical and pathological outcomes of DTC remains unknown \[[@B34]\]. Some studies supported that DTC patients with CLT had a better prognostic outcome compared with those without CLT \[[@B35]\]. Most nodules with benign pathological results and well-differentiated PTC are proliferated from thyroid follicular cells. Benign nodules include follicular carcinoma and oncocytic adenoma. According to [Table 5](#tab5){ref-type="table"}, follicular adenoma is the most common benign thyroid lesions (31.2%); the second most common is benign follicular nodules (16.0%). Malignant lesions such as cvPTC (44.3%) and fvPTC (38.3%) are classified into well-differentiated PTC.

An individual study \[[@B36]\] demonstrated that a predominance of Hürthle cells group led to an increased rate of suspicious GEC results with lower malignant risk than AUS/FLUS or FN/SFN nodules. HCNs partly contributed to the false positive rate of GEC. Considering the recent reclassification of the encapsulated fvPTC as "noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP)", prior studies seldom reclassified fvPTC as NIFTP, which could give rise to unreliable estimates of cancer prevalence and PPV \[[@B37]\]. However, only limited data is available to evaluate the accuracy of GEC in HCN or NIFTP cases.

The Thyroid Imaging Reporting and Data System (TI-RADS) was designed to quantify malignancy of thyroid nodes \[[@B38], [@B39]\]. It was based on suspicious ultrasound features such as solid component, hypoechogenicity or marked hypoechogenicity, irregular margins, microcalcifications or mixed calcifications, and taller-than-wide shape. Gathered data of thyroid nodes showed the sensitivity of TI-RADS was 97.4--99.1% and the NPV was 98.1-99.1% \[[@B40], [@B41]\]. The TI-RADS and American Thyroid Association (ATA) guideline have greatly help physicians stratify the malignancy risk of ITNs. Recently, molecular tests with higher accuracy, together with TI-RADS, were applied for ITNs to decrease the false positive rates.

The BRAF^V600E^ mutation is detected in more than half of papillary thyroid cancer. BRAF mutation has low prevalence in the FN/SFN and AUS/FLUS while high in the SM cytology thyroid lesions \[[@B42], [@B43]\]. However, adding the BRAF V600E mutation to GEC did not improved the diagnostic sensitivity and specificity \[[@B44]\].

The next-generation sequencing panel, ThyroSeq v2, detected 14 cancer gene mutations with more than 1000 hotspots and 42 types of gene fusions or rearrangements in thyroid cancer \[[@B45]\]. A meta-analysis evaluated GEC from 1086 nodules and ThyroSeq v2 from 459 nodules to assess the preoperative diagnostic accuracy of ITNs \[[@B46]\]. Pooled data showed the sensitivity was 98% and 84%, and the specificity was 12% and 78%, respectively. In this meta-analysis, the pooled sensitivity of GEC was higher than our analysis while the pooled specificity was lower than our analysis. Therefore, the superiority of the GEC test lies in ruling-out of malignancy (higher sensitivity) and the ThyroSeq is a better test of 'ruling-in\' thyroid neoplasm (higher specificity).

The risk of malignancy in ITNs was nearly 38.6% in our analysis, indicating that over half patients had underwent undue surgeries and conservative approaches could be considered for ITNs. The final decision of a diagnostic surgery or follow-up depends on US features, histological characteristics, and molecular test results.

5. Conclusions {#sec5}
==============

The present meta-analysis has summarized the previously reported performance of GEC. We regard GEC as an effective approach to rule out malignant lesions in ITNs. Since the most benign nodules with GEC-suspicious results are follicular adenomas, benign follicular nodules and adenomatoid nodules, it is essential to combine other molecular markers to improve the specificity of GEC. The probability of malignancy and clinical management of nodules with GEC-suspicious still needs further investigation.

6. Limitations {#sec6}
==============

Our study has several limitations. First, we failed to obtain the pathologic diagnosis of all the resected nodules, due to the missed original contents in some of the included studies. Second, it is not sure if there were geographic, race, and region variations regarding the GEC results and none of which mentioned the race of participants. Finally, some of the included studies lack the information of long-term follow-up for GEC-benign nodules or when the nodules underwent FNA during follow-up.

We wish to express our warm thanks to those who have contributed to the study.
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###### 

Summary of the studies\' characteristics included in the analysis.

  First Author                   Research Method   Center          Study Time       Site of GEC         Included Nodules
  ------------------------------ ----------------- --------------- ---------------- ------------------- ------------------
  Alexander et al.\[[@B7]\]      P                 Multi Centers   2011.1-2012.8    Veracyte Inc        567
  Sacks et al.\[[@B12]\]         R                 Single Center   2012.1-2014.12   tertiary            567
  Chaudhary et al.\[[@B13]\]     R                 Single Center   2009.7-2015.1    Veracyte Inc        158
  Harrell et al.\[[@B14]\]       U                 Single Center   2011.1-2013.4    Veracyte Inc        58
  Harrison et al.\[[@B15]\]      R                 Single Center   2013.8-2015.3    Veracyte Inc        115
  El Hussein et al.\[[@B16]\]    R                 Single Center   2012.1-2016.7    Veracyte Inc        227
  Abeykoon et al.\[[@B17]\]      R                 Single Center   2014.12-2015.2   Veracyte Inc        34
  Noureldine et al.\[[@B18]\]    R                 Single Center   2012.1-2014.12   Veracyte Inc        273
  McIver et al.\[[@B19]\]        P                 Multi Centers   2011.5-2012.12   Veracyte Inc        105
  Marti et al.\[[@B20]\]         R                 Multi Centers   2013.2-2014.12   Veracyte/tertiary   165
  Lastra et al.\[[@B21]\]        R                 Single Center   2011.2-2014.1    Veracyte Inc        132
  Alexander et al.\[[@B22]\]     R                 Multi Centers   2010.9-2013.1    Veracyte Inc        339
  Yang et al.\[[@B23]\]          R                 Single Center   2012.8-2014.4    Veracyte Inc        187
  Celik et al.\[[@B24]\]         P                 Single Center   2011.12-2014.7   Veracyte Inc        66
  Al-Qurayshi et al.\[[@B25]\]   R                 Single Center   2013.1-2016.2    tertiary            154
  Samulski et al.\[[@B26]\]      R                 Single Center   2011.1-2015.12   U                   294
  Kay-Rivest et al.\[[@B27]\]    R                 Multi Centers   2013.?-2015.?    Veracyte Inc        172
  Han et al.\[[@B29]\]           R                 Single Center   2009.8-2013.3    U                   114

GEC, gene expression classifier; R: retrospective; P: prospective; U: unclear.

###### 

Performance of cytological subtypes indeterminate cases with GEC results (N=1628).

  GEC Results      AUS/FLUS     SFN          SM          Total
  ---------------- ------------ ------------ ----------- -------
  Benign           427(41.6%)   206(39.0%)   18(24.3%)   651
  Suspicious       554(54.0%)   301(57.0%)   55(74.3%)   910
  Unsatisfactory   45(4.4%)     21(4.0%)     1(1.4%)     67
  Total            1026         528          74          1628

AUS/FLUS, atypia of undetermined significance or follicular lesion of undetermined significance; SFN, follicular or Hürthle cell neoplasm or suspicious for follicular neoplasm; SM, suspicious for malignancy.

###### 

Correlation between overall surgical pathologically cases and GEC results (N=1617).

  GEC Results      Surgery Follow-up Results   Total         
  ---------------- --------------------------- ------------- ---------------
                   Benign                      Malignant      
                                                             
  Benign           201(88.2%)                  27(11.8%)     228
  Suspicious       754(55.0%)                  617(55.0%)    1371
  Unsatisfactory   17(94.4%)                   1(5.6%)       18
  Total            972(60.1%)                  645 (39.9%)   1617 (100.0%)

###### 

Pathological diagnoses at resection of Afirma results with cytological subtypes (N=225).

                                          Pathological Diagnoses after Surgery                           
  ------------------------- ------------- -------------------------------------- ----------- ----------- -----------
  FNA Diagnosis             No.(%)        Diagnosis                              No.(%)      Diagnosis   No.(%)
                                                                                                         
  Bethesda III (AUS/FLUS)   139(61.8%)    Follicular adenoma                     14(10.1%)   cvPTC       37(26.6%)
  Adenomatoid nodule        23(16.5%)     fvPTC                                  34(24.5%)               
  Thyroiditis               7(5.0%)       PTC with HC                            2(1.4%)                 
  Graves\' Disease          2(1.4%)       feature                                                        
  HCA                       4(2.9%);      FTC                                    1(0.7%)                 
  Chronic inflammation      1(0.7%)       HCC                                    1(0.7%)                 
  Nodular hyperplasia       12(8.6%)      Others                                 1(0.7%)                 
  Total                     63            Total                                  76                      
                                                                                                         
  Bethesda IV (FN)          77(34.2%)     Follicular adenoma                     10(13.0%)   cvPTC       25(28.6%)
  HCA                       17(22.1%)     fvPTC                                  13(16.9%)               
  Adenomatoid nodule        6(7.8%)       FTC                                    1(1.3%)                 
  Nodular hyperplasia       1(1.3%)       HCC                                    4(5.2%)                 
  Total                     34            Total                                  43                      
                                                                                                         
  Bethesda V (SM)           9(4.0%)       None                                               fvPTC       7(5.5%)
  Total                     0             Others                                 2(1.6%)                 
                                          Total                                  9                       
                                                                                                         
  All Categories            225(100.0%)                                          97                      128

PTC, papillary thyroid carcinoma; FTC: follicular thyroid carcinoma; MTC: medullary thyroid cancer; AN, adenomatous/hyperplasic nodule; cvPTC, classic variant of papillary thyroid carcinoma; fvPTC, follicular variant of papillary thyroid carcinoma; NIFPTC, noninvasive follicular neoplasm with papillary-like nuclear features; PTC, HC feature; HCA, Hürthle cell adenoma; HCC, Hürthle cell carcinoma.

###### 

Summary of final surgical pathology at resection of all surgical nodules (N=960).

                             Pathological Diagnoses after Surgery                                     
  -------------------------- -------------------------------------- -------------------- ------------ ------------
                             Diagnosis                              No.(%)               Diagnosis    No.(%)
                                                                                                      
  Final Surgical Pathology   Follicular adenoma                     139(31.2%)           cvPTC        228(44.3%)
  Benign follicular nodule   71(16.0%)                              FvPTC                197(38.3%)   
  Adenomatoid nodule         58(13.0%)                              PTC, HC                           
  Nodular hyperplasia        56(12.6%)                              features/variant     2(0.4%)      
  HCA                        49(11.0%)                              NIFPTC               15(2.9%)     
  Oncocytic follicular                                              FTC                  39(7.6%)     
  adenoma                    22(4.9%)                               HCC                  24(4.7%)     
  Chronic lymphocytic                                               MTC                  6(1.2%)      
  thyroiditis                9(2.0%)                                Malignant lymphoma   2(0.4%)      
  MNG                        5(1.1%)                                Others               2(0.4%)      
  Graves\' Disease           2(0.4%)                                                                  
  Chronic inflammation       1(0.2%)                                                                  
  Others                     33(7.4%)                                                                 
                                                                                                      
  Total                                                             445(100%)                         515(100%)

PTC, papillary thyroid carcinoma; FTC: follicular thyroid carcinoma; MTC: medullary thyroid cancer; AN, adenomatous/hyperplasic nodule; cvPTC, classic variant of papillary thyroid carcinoma; fvPTC, follicular variant of papillary thyroid carcinoma; NIFPTC, noninvasive follicular neoplasm with papillary-like nuclear features; PTC, HC feature: papillary thyroid carcinoma with Hürthle cell; HCA, Hürthle cell adenoma; HCC, Hürthle cell carcinoma.

###### 

Pooled sensitivities: confidence interval and heterogeneity results.

        Estimate   95% CI           I^2^     Q        P
  ----- ---------- ---------------- -------- -------- ---------
  Se    0.955      (0.935, 0.970)   65.00%   42.87    \<0.001
  Sp    0.221      (0.194, 0.249)   89.10%   137.13   \<0.001
  PLR   1.167      (1.088, 1.252)   77.50%   66.74    \<0.001
  NLR   0.285      (0.199, 0.410)   0.00%    10.63    0.778
  DOR   5.248      (3.425, 8.043)   0.00%    9.42     0.855

Se, sensitivity; Sp, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; I^2^, inconsistency I-square; Q, Chi-square.

###### 

The metaregression of the test.

  Model 1: the variables are method, site, center, and patients                                                        
  --------------------------------------------------------------- ------------- ---------------- ----------- --------- --------------
  Variable                                                        Coefficient   Standard Error   p - value   RDOR      95%CI
                                                                                                                       
  Cte.                                                            1.23          1.3157           0.3719      \-\-\--   \-\-\--
  S                                                               0.109         0.1715           0.5384      \-\-\--   \-\-\--
  Method                                                          -0.253        0.4549           0.5901      0.78      (0.28;2.14)
  Site                                                            -0.08         0.5308           0.8838      0.92      (0.28;3.01)
  Center                                                          0.594         0.8687           0.5096      1.81      (0.26;12.55)
  Patients                                                        0.001         0.0021           0.6037      1         (1.00;1.01)
                                                                                                                       
  Model 2: the variables are method, center, and patients                                                              
                                                                                                                       
  Variable                                                        Coefficient   Standard Error   p - value   RDOR      95%CI
                                                                                                                       
  Cte.                                                            1.09          0.9294           0.2655      \-\-\--   \-\-\--
  S                                                               0.127         0.1264           0.338       \-\-\--   \-\-\--
  Method                                                          -0.277        0.426            0.5289      0.76      (0.30;1.94)
  Center                                                          0.591         0.8685           0.51        1.81      (0.27;12.22)
  Patients                                                        0.001         0.0021           0.5692      1         (1.00;1.01)
                                                                                                                       
  Model 3: the variables are method and center                                                                         
                                                                                                                       
  Variable                                                        Coefficient   Standard Error   p - value   RDOR      95%CI
                                                                                                                       
  Cte.                                                            1.295         0.8614           0.1586      \-\-\--   \-\-\--
  S                                                               0.122         0.1262           0.3527      \-\-\--   \-\-\--
  Method                                                          -0.257        0.4246           0.5569      0.77      (0.31;1.95)
  Center                                                          0.998         0.5232           0.0806      2.71      (0.87;8.48)
                                                                                                                       
  Model 4: the variable is center                                                                                      
                                                                                                                       
  Variable                                                        Coefficient   Standard Error   p - value   RDOR      95%CI
                                                                                                                       
  Cte.                                                            0.892         0.5458           0.126       \-\-\--   \-\-\--
  S                                                               0.11          0.1245           0.3949      \-\-\--   \-\-\--
  Center                                                          1.133         0.473            0.0323      3.11      (1.12;8.63)

RDOR: relative diagnostic odds ratios.

###### 

The bivariate logistic regression of the test.

  Bivariate parameter   Coefficient   Standard error   95% CI
  --------------------- ------------- ---------------- ------------------
  E(logitSe)            4.016         0.482            (3.072,4.960)
  E(logitSp)            -1.866        0.249            (-2.355, -1.377)
  Var(logitSe)          1.373         0.865            (0.399, 4.722)
  Var(logitSp)          0.766         0.352            (0.312, 1.884)
  Corr(logits)          -0.898        0.114            (-0.989, -0.304)

Var: variable; Corr: correlation.

[^1]: Academic Editor: Flavia Prodam
